NCT02184689已完成2 期
Efficacy and Safety of Fexinidazole in Children at Least 6 Years Old and Weighing Over 20 kg With Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open Study, plug-in to the Pivotal Study
Drugs for Neglected Diseases0 个研究点目标入组 125 人开始时间: 2014年5月3日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 125
- 主要终点
- Outcome (success or failure) at the test of cure (ToC)
研究概览
简要总结
The aim of the study is to assess the efficacy and safety of an oral regimen of fexinidazole (once daily for 10 days) in the treatment of stage 1 and stage 2 T.b. gambiense sleeping sickness in children at least 6 years old and over 20 kg bodyweight.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 6 Years 至 14 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Informed consent form signed by one of the parents or the child's legal representative
- •Child assent to participate in the study collected in the presence of an impartial witness
- •Age between 6 and 15 years old
- •> 20 Kg bodyweight
- •Boy or girl
- •Able to ingest at least one complete meal per day (or at least one Plumpy'Nut® sachet)
- •Able to swallow 600mg fexinidazole tablets
- •Karnofsky index > 50
- •Presence of trypanosomes in blood and/or lymph and/or CSF
- •Permanent address and ability to comply with follow-up visit schedule
排除标准
- •Child refusing to be included in the trial
- •Bodyweight < 20 Kg
- •Severe malnutrition, defined as having a BMI below 16 (- 2 Z-score of the norm according to WHO 2007 Growth reference data)
- •Inability to take oral medication
- •Pregnancy or breastfeeding
- •Clinically relevant medical condition other than HAT that, in the Investigator's opinion, may jeopardize subject safety or interfere with participation in the study, including but not limited to significant liver or cardiovascular disease, active documented or suspected infection, central nervous system (CNS) trauma or seizure disorders, coma or altered consciousness
- •Severely deteriorated general condition, such as cardiovascular shock, respiratory distress, or terminal illness
- •Any medical condition (except HAT-specific symptoms) hindering communication with the Investigator as required for the completion of this study
- •Any contraindication to imidazole products (known hypersensitivity to imidazoles)
- •History of HAT treatment in the past 2 years
- •Patients previously enrolled in the study or having already received fexinidazole.
- •Expected follow-up difficulties (migrants, refugees, itinerant vendors, etc.).
- •Current alcohol or drug abuse
- •Clinically significant abnormal laboratory findings, including ASAT and/or ALAT > 2 times ULN // Total bilirubin > 1.5 times ULN // Severe leukopenia (< 2000/mm3) // Potassium (K+) < 3.5 mmol // Any other clinically significant abnormal laboratory value (see details in Investigator Manual)
- •Pregnancy confirmed by a positive urine pregnancy test obtained within 24 hours (h) prior to start of study treatment (see Section 5.8.3 Contraception; p36) for girls over 12 years old and over
- •ECG abnormalities assessed by a central cardiologist
- •QTcF≥ 450 ms, as measured automatically (if first measurement is abnormal, a second assessment will be done at least 10-20 min later, with the patient in resting position).
- •Patients not tested for malaria and/or not treated adequately for this infection
- •Patients not treated adequately for soil transmitted helminthic diseases
研究组 & 干预措施
Fexinidazole
Experimental
干预措施: fexinidazole (Drug)
结局指标
主要结局
Outcome (success or failure) at the test of cure (ToC)
时间窗: 12 months after the end of treatment
Success at 12 months, adapted from the WHO criteria (51), is defined as a cured patient: * Patient alive; * AND no evidence of trypanosomes in any body fluid; * AND WBC ≤20/µL in CSF.
次要结局
未报告次要终点
研究者
相似试验
已完成
2 期
Efficacy and Safety of Fexinidazole in Patients With Stage 1 or Early Stage 2 Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open-label Cohort Study, plug-in to the Pivotal StudyHuman African Trypanosomiasis (HAT)NCT02169557Drugs for Neglected Diseases230
已完成
2 期
Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2Human African Trypanosomiasis (HAT)Sleeping SicknessNCT01685827Drugs for Neglected Diseases394
已完成
2 期
Fexinidazole in Human African Trypanosomiasis Due to T. b. RhodesienseTrypanosoma Brucei Rhodesiense InfectionNCT03974178Drugs for Neglected Diseases45
已完成
1 期
Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the FexinidazoleHuman African TrypanosomiasisNCT00982904Drugs for Neglected Diseases108
已完成
不适用
Diflucan Research For Infant Evaluation Of Antifungal Treatment And Prophylaxis MedicationDeep MycosisNCT01680458Pfizer30